New insights in myositis-specific autoantibodiesGhirardello, Anna; Doria, AndreaCurrent Opinion in Rheumatology: November 2018 - Volume 30 - Issue 6 - p 614–622 doi: 10.1097/BOR.0000000000000548 MYOSITIS AND MYOPATHIES: Edited by Andrea Doria and Anna Ghirardello Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The aim of this study was to provide the most recent evidence on clinical utility of myositis-specific autoantibodies (MSAs) in the management of patients with myositis. Recent findings In the last few years, several evidences have emerged on the clinical and pathogenetic role of established and novel MSA. Antisynthetase antibodies represent a reliable biomarker for pulmonary involvement also in patients with connective tissue diseases other than myositis. Antisignal recognition particle and antihydroxy-3-methylglutaryl coenzyme A reductase autoantibodies are able to induce complement-dependent muscle damage. Dermatomyositis-specific antibodies are useful indicators of clinical diversity. The pivotal role of antitranscription intermediary factor 1γ autoimmune response in adult-age paraneoplastic dermatomyositis has been further asserted. AnticN1A and antifour-and-a-half LIM protein 1 antibodies are newly conceived myositis-related antibody specificities, which can contribute to patients’ stratification into more homogeneous groups. Summary Distinct autoantibody-associated clinical phenotypes can be predicted by extended MSA testing in serum. Standardization and validation of MSA laboratory detection methods is strongly recommended for better supporting myositis diagnosis, management and prognosis definition. Unit of Rheumatology, Department of Medicine, University of Padova, Padova, Italy Correspondence to Andrea Doria, MD, Division of Rheumatology, University of Padova, Via Giustiniani, 2, Padova 35128, Italy. Tel: +39 049 8212202; fax: +39 049 8212191; e-mail: email@example.com Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.